



## Optimer Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference

SAN DIEGO, March 1, 2010 /PRNewswire via COMTEX News Network/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place on March 8, 2010, 4:00 p.m. Eastern Time.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO>)

A live audio webcast of this presentation will be accessible on the Company's website at [www.optimerpharma.com](http://www.optimerpharma.com), under the investors section. A replay of this presentation will be available at the same location for thirty days following the meeting.

### About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is a new class of antibiotics with narrow spectrum bactericidal activity targeted at the site of infection. Recently reported positive top-line results from the second Phase 3 trial confirmed the results from the first Phase 3 trial regarding fidaxomicin's safety and efficacy in patients with *Clostridium difficile* infection. Optimer has also successfully completed two Phase 3 trials with Pruvexel(TM), for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at <http://www.optimerpharma.com>.

#### Contacts

Optimer Pharmaceuticals, Inc.  
Christina Donaghy, Corporate Communications Manager  
John D. Prunty, Chief Financial Officer & VP Finance  
858-909-0736

Porter Novelli Life Sciences  
Jason I. Spark, Vice President  
619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved